AG
CBIO

Algert Global’s Crescent Biopharma CBIO Stock Holding History

Algert Global’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,806
Closed -$254K – 1312
2026
Q1 		$254K Buy
+13,806
New +$158K ﹤0.01% 1046
2022
Q2 		– Sell
-280
Closed -$32K – 1277
2022
Q1 		$32K Buy
280
+18
+7% +$2.11K ﹤0.01% 1153
2021
Q4 		$38K Buy
262
+147
+128% +$26.7K ﹤0.01% 943
2021
Q3 		$25K Buy
+115
New +$24.4K ﹤0.01% 1005

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Algert Global's CBIO Position: Q2 2026 in Review

Algert Global sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 13,806 shares — an estimated $254K sold.

Algert Global first reported a position in CBIO in Q3 2021 and held it in 4 quarters. The position peaked at $254K in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Algert Global reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Algert Global sold 13,806 Crescent Biopharma shares in Q2 2026, an estimated $254K.
  • Algert Global first reported a position in Crescent Biopharma in Q3 2021 and held it in 4 quarters.
  • Algert Global's Crescent Biopharma position peaked at $254K in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.